Please login to the form below

Not currently logged in
Email:
Password:

Kadcyla

This page shows the latest Kadcyla news and features for those working in and with pharma, biotech and healthcare.

Biosimilar Herceptin helps Roche gain new Perjeta recommendation

Biosimilar Herceptin helps Roche gain new Perjeta recommendation

NICE has rejected Roche’s second generation breast cancer drugs Kadcyla and Perjeta numerous times since their EU launch in 2013, though steep price discounts have helped them gain traction with

Latest news

  • Roche submits Kadcyla for FDA Real-Time review Roche submits Kadcyla for FDA Real-Time review

    After three years of treatment, just over 88% of those treated with Kadcyla did not see their breast cancer return, compared to 77% of those treated with Herceptin. ... Expanding Kadcyla's use will help Roche offset Herceptin biosimilars in the US, where

  • Roche preps new Kadcyla filings after phase 3 trial win Roche preps new Kadcyla filings after phase 3 trial win

    Now, Roche has clinical data showing its antibody-drug conjugate Kadcyla offers a second-line of treatment for these patients. ... In the KATHERINE study, giving Kadcyla (ado-trastuzumab emtansine) to women with residual disease despite pre-surgery

  • Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3 Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3

    The second trial will test DS-8201 as a later-line therapy for patients previously treated with other HER2 drugs, including Kadcyla. ... If successful in phase 3, Daiichi-Sankyo’s drug could muscle into Kadcyla’s territory and provide another line of

  • AZ nabs US approval for new leukaemia drug Lumoxiti AZ nabs US approval for new leukaemia drug Lumoxiti

    Seattle Genetics/Takeda’s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast cancer.

  • NICE relents on Kadcyla after Roche pricing negotiations NICE relents on Kadcyla after Roche pricing negotiations

    Roche's HER2-positive breast cancer therapy Kadcyla will be made available on the NHS in England after the drug maker agreed a confidential access deal with cost-effectiveness watchdog NICE. ... Roche has offered an undisclosed price cut which means that

More from news
Approximately 16 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Positive disruption in business intelligence Positive disruption in business intelligence

    Take the recent recommendation by NICE, the UK’s drug-spending policymaker, of Kadcyla, the breast cancer treatment launched by Roche. ... In December 2016, NICE issued draft guidance indicating Kadcyla was too expensive for routine funding on the NHS.

  • Back to the future Back to the future

    and Kadcyla.

  • Pharma deals during August 2013 Pharma deals during August 2013

    The technology enables the development of “armed” antibodies to deliver potent cell-killing agents to cancer cells, sparing nearby healthy cells. Proof-of-concept has been established with Genentech's Kadcyla

  • Pharma deals during April 2013 Pharma deals during April 2013

    This passion has seemingly been ignited further by the recent FDA approvals of Kadcyla (Genentech/ ImmunoGen) and Adcetris (Seattle Genetics) both following impressive clinic trials in HER2 breast cancer and lymphoma,

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics